CORT Q4 2024 Earnings — Corcept Therapeutics Incorporated Revenue & Financial Results | Market Cap Arena

CORTCorcept Therapeutics Incorporated

$4B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$182M+34.3% YoY

Gross Profit

$179M98.4% margin

Operating Income

$25M13.9% margin

Net Income

$30M16.7% margin

EPS (Diluted)

$0.26

QoQ Revenue Growth

-0.4%

Cash Flow

Operating Cash Flow

$59M

Free Cash Flow

$59M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$841M

Total Liabilities

$161M

Stockholders' Equity

$680M

Cash & Equivalents

$128M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$182M	$135M	+34.3%
Gross Profit	$179M	$134M	+34.0%
Operating Income	$25M	$32M	-20.2%
Net Income	$30M	$31M	-3.1%